Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pharvaris N.V. (PHVS)

Pharvaris N.V. (PHVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,535,496
  • Shares Outstanding, K 52,290
  • Annual Sales, $ 0 K
  • Annual Income, $ -145,240 K
  • EBIT $ -185 M
  • EBITDA $ -185 M
  • 60-Month Beta -2.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.46

Options Overview Details

View History
  • Implied Volatility 81.37% (+0.40%)
  • Historical Volatility 85.76%
  • IV Percentile 8%
  • IV Rank 0.37%
  • IV High 188.16% on 11/10/25
  • IV Low 80.98% on 12/03/25
  • Expected Move (DTE 15) 0.55 (2.00%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 12
  • Volume Avg (30-Day) 380
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 7,291
  • Open Int (30-Day) 3,349
  • Expected Range 27.14 to 28.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.71
  • Number of Estimates 6
  • High Estimate -0.61
  • Low Estimate -0.80
  • Prior Year -0.68
  • Growth Rate Est. (year over year) -4.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.02 +31.73%
on 11/07/25
29.80 -7.07%
on 12/04/25
+6.05 (+27.96%)
since 11/04/25
3-Month
20.65 +34.09%
on 10/17/25
29.80 -7.07%
on 12/04/25
+5.71 (+25.98%)
since 09/04/25
52-Week
11.51 +140.57%
on 04/10/25
29.80 -7.07%
on 12/04/25
+7.69 (+38.45%)
since 12/04/24

Most Recent Stories

More News
Stocks Climb on Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up by +0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.20%. December...

MSTR : 186.01 (-1.26%)
AMAT : 269.44 (+0.30%)
GTLB : 37.51 (-0.85%)
ACHC : 14.64 (-0.34%)
DHI : 160.73 (-2.59%)
ADI : 277.26 (-0.35%)
FISV : 66.06 (-1.33%)
GLXY : 27.57 (+1.92%)
BLDR : 111.01 (-3.00%)
TXN : 180.12 (-1.36%)
$IUXX : 25,581.70 (-0.10%)
COIN : 274.05 (-1.04%)
Stocks Recover on Fed Rate Cut Expectations

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.18%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.06%. December E-mini S&P...

MSTR : 186.01 (-1.26%)
GTLB : 37.51 (-0.85%)
ACHC : 14.64 (-0.34%)
DHI : 160.73 (-2.59%)
FISV : 66.06 (-1.33%)
GLXY : 27.57 (+1.92%)
BLDR : 111.01 (-3.00%)
TXN : 180.12 (-1.36%)
$IUXX : 25,581.70 (-0.10%)
COIN : 274.05 (-1.04%)
ASML : 1,110.08 (-2.70%)
ZNH26 : 112-245 (+0.04%)
Stocks Pressured by Labor Market Weakness and AI-Demand Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.49%. December E-mini S&P...

MSTR : 186.01 (-1.26%)
GTLB : 37.51 (-0.85%)
ACHC : 14.64 (-0.34%)
DHI : 160.73 (-2.59%)
GLXY : 27.57 (+1.92%)
BLDR : 111.01 (-3.00%)
TXN : 180.12 (-1.36%)
$IUXX : 25,581.70 (-0.10%)
M : 22.32 (-0.62%)
COIN : 274.05 (-1.04%)
ZNH26 : 112-245 (+0.04%)
PHVS : 27.69 (-5.70%)
Analysts Conflicted on These Healthcare Names: Abbott Laboratories (ABT), Amgen (AMGN) and Pharvaris (PHVS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Abbott Laboratories (ABT – Research Report), Amgen (AMGN – Research Report) and Pharvaris (PHVS – Research Report).Elevate...

PHVS : 27.69 (-5.70%)
ABT : 125.40 (+0.09%)
AMGN : 340.16 (-1.52%)
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Pharvaris (PHVS) and Stevanato Group (STVN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Galapagos (GLPG – Research Report), Pharvaris (PHVS – Research Report) and Stevanato Group (STVN –...

PHVS : 27.69 (-5.70%)
GLPG : 31.77 (unch)
STVN : 22.92 (-1.88%)
Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)

In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Pharvaris, with a price target of $34.00. The company’s shares closed last Friday at $23.39.Elevate Your Investing...

PHVS : 27.69 (-5.70%)
Manufacturing, Housing Due Next Week in Canada

Monday U.S. Featured Earnings Legend Biotech Corporation (NASDAQ: LEGN) (Q1) EPS ...

BABA : 157.44 (-0.40%)
SONY : 28.29 (-0.60%)
AMAT : 269.44 (+0.30%)
CRDL.TO : 1.33 (unch)
LEGN : 27.81 (+0.22%)
CSCO : 77.76 (+0.01%)
TJX : 150.30 (+0.16%)
PHVS : 27.69 (-5.70%)
CPRT : 38.80 (-0.13%)
RBC : 443.22 (+1.16%)
PBH.TO : 98.94 (-0.19%)
ORE.TO : 1.65 (-0.60%)
Jobs Figures Roll out Next Week

Monday U.S. Economic Lookahead S&P U.S. manufacturing PMI (final) (Mar.) Construction ...

PVH : 77.16 (-11.87%)
CAG : 16.95 (-1.22%)
LW : 59.76 (-1.21%)
BYRN : 19.26 (+5.19%)
MVST : 3.72 (+5.68%)
RPM : 105.00 (-0.87%)
LEVI : 22.19 (-1.11%)
PHVS : 27.69 (-5.70%)
PLAY : 18.18 (+3.77%)
AYI : 374.72 (+1.41%)
KNT.TO : 20.57 (+1.48%)
SGML : 9.98 (-0.50%)
Why Shares of Pharvaris N.V. Are Up Tuesday

Promising news from the Food and Drug Administration spurred the healthcare stock's rise.

PHVS : 27.69 (-5.70%)
Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference

ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 27.69 (-5.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema and other bradykinin-B2-receptor-mediated...

See More

Key Turning Points

3rd Resistance Point 31.51
2nd Resistance Point 30.65
1st Resistance Point 29.17
Last Price 27.69
1st Support Level 26.83
2nd Support Level 25.98
3rd Support Level 24.50

See More

52-Week High 29.80
Last Price 27.69
Fibonacci 61.8% 22.81
Fibonacci 50% 20.65
Fibonacci 38.2% 18.50
52-Week Low 11.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar